Skip to main content
Top
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | osteosarcoma | Correction

Correction to: CCR9 initiates epithelial–mesenchymal transition by activating Wnt/β-catenin pathways to promote osteosarcoma metastasis

Authors: Haoran Kong, Wenhui Yu, Zhuning Chen, Haonan Li, Guiwen Ye, Jiacong Hong, Zhongyu Xie, Keng Chen, Yanfeng Wu, Huiyong Shen

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Excerpt

In this article [1], the annotation was wrong in Fig. 5B and in Fig. 6C, the figure of HOS cells treated by OE-CCR9 + XAV 939 at 0 h was wrong. The revised Figure 5 and its legend and Figure 6 are given below.
Metadata
Title
Correction to: CCR9 initiates epithelial–mesenchymal transition by activating Wnt/β-catenin pathways to promote osteosarcoma metastasis
Authors
Haoran Kong
Wenhui Yu
Zhuning Chen
Haonan Li
Guiwen Ye
Jiacong Hong
Zhongyu Xie
Keng Chen
Yanfeng Wu
Huiyong Shen
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02569-z

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine